Interestingly, all CTCs analyzed in the advanced prostate cancer stage presented CD61+ expression while three localized stage patients showed CTCs with absence of CD61 expression (CK+/CD61-) (Table 1). The gene discussed is ITGB3; the disease is prostate carcinoma.